Kenvue Inc. (NYSE:KVUE) Shares Purchased by Shell Asset Management Co.

Shell Asset Management Co. boosted its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 68.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,606 shares of the company's stock after purchasing an additional 10,378 shares during the period. Shell Asset Management Co.'s holdings in Kenvue were worth $547,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Kiley Juergens Wealth Management LLC grew its stake in Kenvue by 1.9% in the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock worth $579,000 after acquiring an additional 500 shares in the last quarter. Principle Wealth Partners LLC increased its stake in shares of Kenvue by 3.7% during the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock valued at $303,000 after buying an additional 500 shares during the period. White Pine Capital LLC raised its holdings in shares of Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock valued at $1,165,000 after acquiring an additional 542 shares in the last quarter. Deseret Mutual Benefit Administrators grew its holdings in Kenvue by 29.0% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock worth $54,000 after acquiring an additional 568 shares in the last quarter. Finally, SRS Capital Advisors Inc. raised its holdings in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

KVUE stock traded down $0.52 during mid-day trading on Thursday, reaching $23.49. 13,277,432 shares of the company's stock were exchanged, compared to its average volume of 16,420,319. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $25.17. The stock's 50 day moving average is $23.22 and its 200 day moving average is $22.62. The company has a market cap of $45.06 billion, a price-to-earnings ratio of 44.31, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The firm had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The firm's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.28 EPS. On average, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.49%. Kenvue's dividend payout ratio is currently 149.09%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on KVUE shares. Evercore ISI initiated coverage on shares of Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective on the stock. Barclays lifted their target price on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research note on Monday, May 12th. Redburn Atlantic assumed coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target for the company. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Finally, Citigroup increased their target price on shares of Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a research report on Friday, May 9th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.